Moloney Securities Asset Management LLC Buys 469 Shares of Hologic, Inc. (NASDAQ:HOLX)

Moloney Securities Asset Management LLC grew its stake in Hologic, Inc. (NASDAQ:HOLX) by 3.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,839 shares of the medical equipment provider’s stock after acquiring an additional 469 shares during the period. Moloney Securities Asset Management LLC’s holdings in Hologic were worth $1,046,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of HOLX. Innealta Capital LLC acquired a new stake in shares of Hologic during the 2nd quarter worth approximately $25,000. Wolff Wiese Magana LLC acquired a new stake in shares of Hologic during the 3rd quarter worth approximately $25,000. iA Global Asset Management Inc. acquired a new stake in shares of Hologic during the 1st quarter worth approximately $37,000. Sunbelt Securities Inc. acquired a new stake in shares of Hologic during the 2nd quarter worth approximately $37,000. Finally, Cromwell Holdings LLC grew its position in shares of Hologic by 330.2% during the 3rd quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock worth $44,000 after buying an additional 416 shares during the period. 94.73% of the stock is owned by institutional investors.

Hologic Stock Performance

Shares of HOLX opened at $78.80 on Wednesday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.32 and a current ratio of 3.99. Hologic, Inc. has a twelve month low of $66.93 and a twelve month high of $84.67. The firm’s 50 day moving average price is $81.06 and its two-hundred day moving average price is $78.08. The firm has a market cap of $18.30 billion, a P/E ratio of 26.80, a PEG ratio of 2.98 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting analysts’ consensus estimates of $1.01. The business had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The firm’s revenue for the quarter was up 4.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.89 earnings per share. On average, analysts forecast that Hologic, Inc. will post 4.09 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. UBS Group lifted their price target on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research report on Tuesday. Royal Bank of Canada boosted their price objective on shares of Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a report on Tuesday. Evercore ISI boosted their price objective on shares of Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a report on Tuesday, October 1st. Needham & Company LLC restated a “buy” rating and set a $90.00 price objective on shares of Hologic in a report on Tuesday, October 15th. Finally, Stephens restated an “overweight” rating and set a $92.00 price objective on shares of Hologic in a report on Tuesday, July 30th. Five equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, Hologic currently has a consensus rating of “Moderate Buy” and an average price target of $89.25.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.